Vol 26, No 2 (2021)
Letter to the Editor
Published online: 2021-03-04
Second line of treatment for HER2 positive gastric cancer: an evolving issue
Rep Pract Oncol Radiother 2021;26(2):316-317.
Abstract
Not available
Keywords: trastuzumabpaclitaxelramucirumabsecond linegastric cancer
References
- Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020; 38(17): 1919–1927.
- Roviello G, D'Angelo A, Roudi R, et al. Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. J Oncol. 2019; 2019: 5692317.
- Roviello G, Fancelli S, Gatta Michelet MR, et al. TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination. Crit Rev Oncol Hematol. 2020; 152: 102987.
- Afshari F, Soleyman-Jahi S, Keshavarz-Fathi M, et al. The promising role of monoclonal antibodies for gastric cancer treatment. Immunotherapy. 2019; 11(4): 347–364.
- De Vita F, Borg C, Farina G, et al. Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. Future Oncol. 2019; 15(23): 2723–2731.
- Ter Veer E, van den Ende T, Creemers A, et al. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis. Acta Oncol. 2018; 57(12): 1599–1604.
- Shitara K, Bang YJ, Iwasa S, et al. DESTINY-Gastric01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020; 382(25): 2419–2430.
- Alameddine RS, Otrock ZK, Awada A, et al. Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges. Curr Opin Oncol. 2013; 25(3): 313–324.